Kolon TissueGene Expands TG-C Cell Gene Therapy to Spinal Indications with FDA Approval
核心洞察
Kolon TissueGene (搜索) received FDA approval in December 2023 to expand TG-C cell gene therapy clinical trials from knee osteoarthritis (搜索) to spinal indications, marking the first expansion to other treatment targets.
The company plans to initiate Phase 1 spinal clinical trials in the second half of 2026, treating 24 patients over 24 months using the same formulation currently in Phase 3 knee trials.
TG-C recently secured patent protection in Canada, joining seven other countries, with the patent establishing quantitative evaluation standards for the therapy's effectiveness and quality.
Kolon TissueGene (搜索) has received regulatory approval to expand its cell gene therapy TG-C beyond knee osteoarthritis (搜索) to spinal indications, marking a significant milestone in the company's strategy to address multiple degenerative musculoskeletal diseases (搜索). The U.S. Food and Drug Administration approved the indication expansion in December 2023, acknowledging the therapy's potential for treating spinal conditions.
Clinical Development Timeline
The company plans to establish a clinical trial execution plan and select vendors in the second half of this year, with completion of clinical research organization (CRO) selection and contracting targeted for the first quarter of 2025. Phase 1 spinal clinical trials are scheduled to begin in the second half of 2026, involving 24 patients who will receive TG-C treatment and undergo 12 evaluations over a 24-month period.
"This project was able to dramatically shorten the time by entering spinal clinical trials based on data from TG-C accumulated through knee clinical," said Kolon TissueGene (搜索) CEO Noh Moon-jong. The spinal trials will utilize the same TG-C formulation currently being tested in Phase 3 knee osteoarthritis (搜索) trials in the United States.
Patent Protection Strengthens Global Position
Kolon Life Sciences (搜索) announced that TG-C has secured patent registration in Canada, adding to existing protections in the United States, Japan, China, Australia, Hong Kong, and Singapore. The Canadian patent establishes quantitative evaluation standards for TG-C's effectiveness and quality, focusing on expression levels of TGF-β1 (搜索) secreted by transgenic cells and TSP-1 (搜索) produced by chondrocytes.
"The Canadian patent registration has further strengthened the foundation for objectively evaluating the effectiveness of TG-C's osteoarthritis (搜索) treatment," said Kim Sun-jin, CEO of Kolon Life Sciences (搜索). "This is an important achievement in enhancing scientific credibility to enter the global market."
Market Opportunity and Expansion Strategy
The spinal indication represents a substantial market opportunity, with the U.S. spinal indication market estimated between $1 billion and $3 billion according to 2020 data from Brother Consulting. CEO Jeon Seung-ho noted that spinal disease (搜索) is "a representative degenerative musculoskeletal disease along with knee osteoarthritis (搜索), and the number of patients is very high and current treatment methods are limited."
The company plans sequential expansion beyond spine to hip joint indications, with TG-C already approved by the FDA to proceed directly to Phase 2 clinical trials for hip treatments. Recent patent acquisitions in Europe and Australia provide exclusive technology use and rights protection through 2040.
Therapy Mechanism and Composition
TG-C is a cell gene therapy composed of two components administered by mixing allogeneic cartilage-derived chondrocytes with irradiated TGF-β1 (搜索) genes at a 3:1 ratio, then injecting the mixture into joint cavities. The therapy works by suppressing joint inflammation, relieving pain, and improving joint function and structure.
The Canadian cell therapy market is projected to grow at an annual average rate of 24.29% from 2023, reaching approximately $1.06 billion by 2033, according to global market research firm Spiral Insight. If Kolon TissueGene (搜索) receives product licensing approval for knee indications, the company will secure exclusive sales rights for 12 years in the United States and 10 years in Europe following marketing approval.